CER And Personalized Medicine Are "Synergistic" - FDA's Woodcock
Executive Summary
The goals of comparative effectiveness research and personalized medicine might appear at odds or at least as leading to divergent paths, with one focusing on the best treatment for a population and the other on the best treatment for an individual
You may also be interested in...
CER's Place In Drug Development Is A Work In Progress, FDA Says
FDA has a lot of work to do before it can determine how comparative effectiveness research might play into its evaluation of new drug approvals or labeling changes, Chief Scientist and Acting Deputy Commissioner for Science and Public Health Jesse Goodman told a conference sponsored by the Friends of Cancer Research June 18
CER's Place In Drug Development Is A Work In Progress, FDA Says
FDA has a lot of work to do before it can determine how comparative effectiveness research might play into its evaluation of new drug approvals or labeling changes, Chief Scientist and Acting Deputy Commissioner for Science and Public Health Jesse Goodman told a conference sponsored by the Friends of Cancer Research June 18
Where's the Economic Stimulus for Personalized Medicine?
With so many billions in funding flowing from the US government through the NIH and a consistent buzz around comparative effectiveness research, the question "Where is the economic stimulus money for personalized medicine?" is one that advocates and innovators are beginning to ask in earnest.